How can breakthrough technology serve the emerging markets?

In January 2010 Johan Van Hoof was appointed Global Therapeutic Area Head for Infectious Diseases & Vaccines, Pharmaceuticals Group, JnJ. As of June 2011, Johan took additional responsibilities, as COO Crucell, the Vaccine Company acquired by JnJ in February 2011. In this role he oversees Development and Manufacturing as Crucell. Entering the field of vaccines, J&J aims to broaden its …